SELLAS Life Sciences Group Enters Material Definitive Agreement
Ticker: SLS · Form: 8-K · Filed: Oct 3, 2025 · CIK: 1390478
| Field | Detail |
|---|---|
| Company | Sellas Life Sciences Group, Inc. (SLS) |
| Form Type | 8-K |
| Filed Date | Oct 3, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-definitive-agreement
TL;DR
SELLAS Life Sciences Group signed a big deal on Oct 1st, details TBD.
AI Summary
On October 1, 2025, SELLAS Life Sciences Group, Inc. entered into a material definitive agreement. The filing does not provide specific details on the agreement or any associated financial figures.
Why It Matters
This filing indicates a significant new development for SELLAS Life Sciences Group, potentially impacting its future operations and strategic direction.
Risk Assessment
Risk Level: medium — The lack of specific details in the filing regarding the material definitive agreement introduces uncertainty about its nature and potential impact.
Key Players & Entities
- SELLAS Life Sciences Group, Inc. (company) — Registrant
- October 1, 2025 (date) — Date of earliest event reported
FAQ
What is the nature of the material definitive agreement entered into by SELLAS Life Sciences Group?
The filing does not specify the nature of the material definitive agreement.
When was the material definitive agreement entered into?
The material definitive agreement was entered into on October 1, 2025.
Does the filing provide any financial details related to the agreement?
No, the filing does not provide any financial details related to the agreement.
What is the exact title of the filing?
The filing is a Form 8-K.
What is the company's state of incorporation?
The company is incorporated in Delaware.
Filing Stats: 511 words · 2 min read · ~2 pages · Grade level 10.2 · Accepted 2025-10-03 16:05:31
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share SLS The Nasdaq St
Filing Documents
- tm2527877d1_8k.htm (8-K) — 28KB
- tm2527877d1_ex10-1.htm (EX-10.1) — 17KB
- 0001104659-25-096643.txt ( ) — 211KB
- sls-20251001.xsd (EX-101.SCH) — 3KB
- sls-20251001_lab.xml (EX-101.LAB) — 33KB
- sls-20251001_pre.xml (EX-101.PRE) — 22KB
- tm2527877d1_8k_htm.xml (XML) — 4KB
01
Item 1.01 Entry into a Material Definitive Agreement. On October 1, 2025, SELLAS Life Sciences Group, Inc. (the "Company"), as subtenant, entered into a Letter Agreement with Times Square Tower Associates LLC (the "Sublandlord") relating to a certain sublease (as amended) of certain premises located at Times Square Tower, 7 Times Square, New York, New York (the "Sublease"). The Letter Agreement provides for the extension of the expiration date of the Sublease from September 30, 2026 to September 30, 2027. The annual rent remains unchanged. The foregoing description of the Letter Agreement is qualified in its entirety by reference to the Letter Agreement, which is filed as Exhibit 10.1 hereto and incorporated herein by reference. 2
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 10.1 Letter Agreement by and between SELLAS Life Sciences Group, Inc. and Times Square Tower Associates LLC 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 3
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SELLAS Life Sciences Group, Inc. Date: October 3, 2025 By: /s/ John T. Burns Name: John T. Burns Title: Senior Vice President, Chief Financial Officer 4